Literature DB >> 12091349

Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable.

Per Levéen1, Jonas Larsson, Mats Ehinger, Corrado M Cilio, Martin Sundler, Lottie Jansson Sjöstrand, Rikard Holmdahl, Stefan Karlsson.   

Abstract

Recent studies in mouse models deficient in transforming growth factor beta (TGF-beta) signaling have documented TGF-beta as one of the major regulators of immune function. TGF-beta1-null animals demonstrated massive autoimmune inflammation affecting multiple organs, but attempts to transfer the phenotype to normal animals by bone marrow transplantation only resulted in minor inflammatory lesions. We wanted to ask whether a lethal inflammatory phenotype would develop following transplantation of bone marrow deficient for the TGF-beta type II receptor (TbetaRII) gene to normal recipient animals. The TbetaRII-null mutation would generate a cell autonomous phenotype that cannot be reverted by the influence of endocrine or paracrine TGF-beta derived from the recipient animal. We have generated conditional knockout mice in which the TbetaRII gene is disrupted upon induction with interferon-alphabeta or polyI:polyC. We show that induction of TbetaRII gene disruption in these mice by polyI:polyC results in a lethal inflammatory disease. Importantly, bone marrow from conditional knockout mice transferred to normal recipent mice caused a similar lethal inflammation, regardless of whether induction of TGF-beta receptor deficiency occurred in donor animals before, or in recipient animals after transplantation. These results show that TGF-beta signaling deficiency within cells of hematopoietic origin is sufficient to cause a lethal inflammatory disorder in mice. This animal model provides an important tool to further clarify the pathogenic mechanisms in animals deficient for TGF-beta signaling and the importance of TGF-beta to regulate immune functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091349     DOI: 10.1182/blood.v100.2.560

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  91 in total

Review 1.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

Review 2.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

3.  TGF-β signalling prevents pancreatic beta cell death after proliferation.

Authors:  Chen Lei; Xiaoling Zhou; Yi Pang; Yuanyuan Mao; Xixuan Lu; Meijuan Li; Jie Zhang
Journal:  Cell Prolif       Date:  2015-04-13       Impact factor: 6.831

4.  Defective retinal vascular endothelial cell development as a consequence of impaired integrin αVβ8-mediated activation of transforming growth factor-β.

Authors:  Thomas D Arnold; Gina M Ferrero; Haiyan Qiu; Isabella T Phan; Rosemary J Akhurst; Eric J Huang; Louis F Reichardt
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

5.  Inactivation of TGFbeta signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome.

Authors:  Heiko Wurdak; Lars M Ittner; Karl S Lang; Per Leveen; Ueli Suter; Jan A Fischer; Stefan Karlsson; Walter Born; Lukas Sommer
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

Review 6.  Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.

Authors:  Justin C Hewlett; Jonathan A Kropski; Timothy S Blackwell
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

7.  TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.

Authors:  Stoyan N Angelov; Jie Hong Hu; Hao Wei; Nathan Airhart; Minghui Shi; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

8.  Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.

Authors:  Arthur C K Chung; Haiyan Zhang; Yao-Zhong Kong; Jia-Ju Tan; Xiao R Huang; Jeffrey B Kopp; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

9.  Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice.

Authors:  Jie Hong Hu; Hao Wei; Mia Jaffe; Nathan Airhart; Liang Du; Stoyan N Angelov; James Yan; Julie K Allen; Inkyung Kang; Thomas N Wight; Kate Fox; Alexandra Smith; Rachel Enstrom; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-22       Impact factor: 8.311

10.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Authors:  Shun Takaku; Masaki Terabe; Elena Ambrosino; Judy Peng; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.